| Literature DB >> 25247786 |
Andrea J Glenn1, Kristina A Fielding2, Jianmin Chen3, Elena M Comelli4, Wendy E Ward5.
Abstract
Inflammatory bowel disease (IBD) is an idiopathic disease that can impair bone metabolism. Low vitamin D status has been implicated in its progress. This study used interleukin (IL)-10 knockout (KO) mice, that develop an intestinal inflammation when housed in a non-sterile environment, to determine if supplementation with vitamin D3 throughout life could mitigate inflammation and attenuate the lower bone mineral content (BMC) and density (BMD), and bone strength. Female IL-10 KO mice were randomized 25 or 5000 IU vitamin D3/kg diet throughout pregnancy and lactation. At weaning, offspring received the same or opposite diet as their mother until age three months. Body weight growth was similar among groups within a sex. At three months of age, there were no differences in inflammation and gene expression in the colon of offspring. Male offspring exposed to continuous 25 IU vitamin D3/kg diet had lower (p < 0.001) colonic VDR expression and those exposed only to low vitamin D3 until weaning had higher serum IL-6. There were no differences in femur or vertebral BMC, BMD or bone strength. In summary, long-term exposure to vitamin D3 did not attenuate intestinal inflammation or preserve bone mineral or bone strength. Thus, supplementation with vitamin D3 does not exert anti-inflammatory effects in this mouse model that mimics human inflammatory bowel disease.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25247786 PMCID: PMC4179191 DOI: 10.3390/nu6093847
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Composition of modified AIN93G purified rodent diet containing high or low levels of vitamin D.
| Ingredient | Unit | Value |
|---|---|---|
| Crude Protein | % | 17.9 |
| Crude Fat | % | 7.0 |
| Crude Fibre | % | 4.8 |
| Moisture | % | 7.0 |
| Ash | % | 4.2 |
| Arginine | % | 0.70 |
| Lysine | % | 1.48 |
| Methionine | % | 0.56 |
| Cystine | % | 0.30 |
| Tryptophan | % | 0.21 |
| Histidine | % | 0.51 |
| Leucine | % | 1.76 |
| Isoleucine | % | 1.14 |
| Phenylalanine | % | 0.96 |
| Tyrosine | % | 0.98 |
| Threonine | % | 0.76 |
| Valine | % | 1.00 |
| Calcium | mg/kg | 5000 |
| Phosphorus | mg/kg | 1561 |
| Potassium | mg/kg | 3600 |
| Sodium | mg/kg | 1019 |
| Magnesium | mg/kg | 507 |
| Iron | mg/kg | 35 |
| Zinc | mg/kg | 30 |
| Manganese | mg/kg | 10 |
| Copper | mg/kg | 6.0 |
| Iodine | mg/kg | 0.2 |
| Vitamin A | IU/g | 4.00 |
| Vitamin D3 | IU/g | 0.025 † or 5.00 †† |
| Alpha-Tocopherol | IU/g | 75.00 |
| Thiamine | mg | 5.0 |
| Riboflavin | mg | 6.0 |
| Niacin | mg | 30 |
| Pantothenic Acid | mg | 15.0 |
| Pyridoxine | mg | 6.0 |
| Folic Acid | mg | 2.0 |
| Biotin | mcg | 200 |
| Vitamin B12 | mcg | 25.0 |
| Vitamin K | mcg | 750 |
†: Vitamin D content of modified low vitamin D AIN93G diet (Diet #119289); ††: Vitamin D content of modified high vitamin D AIN93G diet (Diet #119290).
Body weight of offspring at 1 month of age (weaning) and 3 months of age (necropsy).
| Age | HH | HL | LH | LL | |
|---|---|---|---|---|---|
| 1 month (g) | 12.1 ± 0.1 | 12.3 ± 1.1 | 12.4 ± 0.8 | 12.7 ± 0.6 | 0.96 |
| 3 months (g) | 20.0 ± 1.0 | 20.3 ± 1.1 | 19.8 ± 1.2 | 20.2 ± 1.3 | 0.95 |
| 1 month (g) | 13.7 ± 0.8 | 12.9 ± 1.1 | 14.5 ± 0.8 | 14.1 ± 0.0 | 0.10 |
| 3 months (g) | 23.5 ± 0.7 | 23.7 ± 1.1 | 23.8 ± 1.8 | 23.5 ± 0.8 | 0.94 |
Data are means ± SEM, n = 16/group.
Colon severity score, serum 25(OH)D and cytokines of offspring at three months of age.
| Outcomes | HH | HL | LH | LL | |||
|---|---|---|---|---|---|---|---|
| Colon severity score | 1.4 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.3 | 1.4 ± 0.3 | 0.57 | 0.56 | 0.07 |
| Serum 25(OH)D (nmol/L) | 99.1 ± 4.1 a | 22.7 ± 1.5 b | 93.6 ± 7.5 a | 20.6 ± 0.6 b | 0.39 | <0.001 | 0.70 |
| IL-1α (pg/mL) | 153.5 ± 47.9 | 77.8 ± 55.3 | 175.2 ± 47.9 | 125.9 ± 60.6 | 0.51 | 0.25 | 0.81 |
| IL-6 (pg/mL) | 7.6 ± 7.6 | 12.9 ± 9.8 | 17.8 ± 7.6 | 28.8 ± 7.6 | 0.13 | 0.33 | 0.73 |
| IL-17 (pg/mL) | 17.0 ± 4.8 | 8.9 ± 4.8 | 14.8 ± 5.4 | 14.2 ± 4.8 | 0.75 | 0.39 | 0.45 |
| TNF-α (pg/mL) | 10.7 ± 2.6 | 6.1 ± 2.6 | 12.8 ± 2.8 | 7.4 ± 2.6 | 0.52 | 0.07 | 0.88 |
| Colon severity score | 1.5 ± 0.2 | 1.5 ± 0.2 | 1.4 ± 0.2 | 1.7 ± 0.2 | 0.93 | 0.26 | 0.84 |
| Serum 25(OH)D (nmol/L) | 93.8 ± 2.7 a | 26.0 ± 1.6 b | 101.6 ± 10.3 a | 23.0 ± 2.2 b | 0.66 | <0.001 | 0.34 |
| IL-1α (pg/mL) | 60.6 ± 13.9 | 62.9 ± 18.1 | 42.2 ± 18.1 | 42.2 ± 18.0 | 0.28 | 0.94 | 0.96 |
| IL-6 (pg/mL) | 15.6 ± 7.1 | 13.9 ± 7.6 | 30.7 ± 7.1 | 37.3 ± 8.7 | 0.01 | 0.75 | 0.60 |
| IL-17 (pg/mL) | 26.4 ± 4.9 | 21.9 ± 5.2 | 20.8 ± 4.9 | 25.3 ± 5.6 | 0.83 | 0.99 | 0.39 |
| TNF-α (pg/mL) | 12.3 ± 2.1 | 10.9 ± 2.3 | 10.2 ± 1.9 | 11.3 ± 2.3 | 0.68 | 0.94 | 0.57 |
Data are means ± SEM. Means in a row with superscripts without a common letter differ; p ≤ 0.05; Colon severity score (n = 13/group); serum 25(OH)D3 (n = 5/group); cytokines (n = 9–10/group).
Figure 1Histological assessment of colonic inflammation. (A) Score 0: no inflammation with normal crypt and goblet cells (arrow); m: mucosa; s: submucosa; ms: muscularis. H & E, 400×; (B) Score 1: minimal evidence of inflammatory infiltrate (arrow), H & E, 400×; (C) Score 2: significant evidence of inflammatory infiltrate (arrow), H & E, 400×; (D) Score 3: significant evidence of inflammatory infiltrate with goblet cell depletion (arrow), H & E, 400×; (E) Score 4: severe inflammation characterized by widespread infiltration with inflammatory cells, formation of crypt abscesses (arrows), mucosal thickening, submucosal cell infiltration, a decrease in goblet cells and destruction of architecture, H & E, 400×.
Figure 2Representative microphotography of proximal colonic VDR expression in male offspring IL-10 KO mice fed diet supplemented with high vitamin D or low vitamin D. (A) Group HH; (B) Group HL; (C) Group LH; (D) Group LL. 400×. Showing mucosa layer only. n = 13/group.
Bone outcomes of offspring at three months of age: serum markers, biomechanical bone strength, and bone mineral content and density.
| Bone Outcomes | HH | HL | LH | LL | |||
|---|---|---|---|---|---|---|---|
| RANKL (pg/mL) | 115 ± 10 a,b | 87 ± 10 a | 115 ± 9 a,b | 139 ± 10 b | 0.009 | 0.85 | 0.01 |
| OPG (pg/mL) | 1795 ± 182 | 1829 ± 182 | 1501 ± 172 | 1681 ± 193 | 0.23 | 0.56 | 0.68 |
| OPG/RANKL ratio | 16 ± 2 | 25 ± 5 | 12 ± 2 | 13 ± 2 | 0.004 | 0.06 | 0.16 |
| Femur midpoint yield load (N) | 10.1 ± 0.2 | 8.7 ± 0.4 | 9.4 ± 0.3 | 9.1 ± 0.4 | 0.66 | 0.005 | 0.11 |
| Femur midpoint peak load (N) | 19.8 ± 0.6 | 18.4 ± 0.4 | 18.6 ± 0.6 | 18.2 ± 0.4 | 0.17 | 0.09 | 0.34 |
| Femur neck peak load (N) | 10.0 ± 0.4 | 9.6 ± 0.4 | 10.1 ± 0.4 | 9.8 ± 0.3 | 0.71 | 0.33 | 0.84 |
| LV2 peak load (N) | 45.4 ± 1.9 | 44.1 ± 1.5 | 47.3 ± 1.5 | 46.2 ± 1.4 | 0.21 | 0.45 | 0.95 |
| Whole femur BMC (mg) | 20.7 ± 0.74 | 19.8 ± 0.89 | 19.1 ± 0.73 | 19.1 ± 0.94 | 0.20 | 0.92 | 0.34 |
| Whole femur BMD (mg/mm2) | 6.49 ± 0.16 | 6.41 ± 0.19 | 6.23 ± 0.18 | 6.18 ± 0.18 | 0.15 | 0.67 | 0.92 |
| 1/3 prox. femur BMC (mg) | 7.92 ± 0.24 | 7.62 ± 0.33 | 7.27 ± 0.25 | 7.52 ± 0.32 | 0.20 | 0.92 | 0.34 |
| 1/3 prox. femur BMD (mg/mm2) | 6.95 ± 0.15 | 6.87 ± 0.18 | 6.72 ± 0.19 | 6.62 ± 0.16 | 0.17 | 0.62 | 0.96 |
| LV4 BMC (mg) | 6.20 ± 0.39 | 6.49 ± 0.21 | 5.95 ± 0.38 | 5.63 ± 0.35 | 0.10 | 0.96 | 0.36 |
| LV4 BMD (mg/mm2) | 5.48 ± 0.01 | 5.73 ± 0.16 | 5.25 ± 0.29 | 5.29 ± 0.26 | 0.26 | 0.62 | 0.72 |
| RANKL (pg/mL) | 116 ± 10 | 119 ± 10 | 119 ± 10 | 109 ± 10 | 0.74 | 0.72 | 0.49 |
| OPG (pg/mL) | 2016 ± 214 | 1992 ± 226 | 2027 ± 240 | 2154 ± 226 | 0.70 | 0.82 | 0.74 |
| OPG/RANKL ratio | 19 ± 2 | 18 ± 4 | 20 ± 5 | 22 ± 4 | 0.52 | 0.89 | 0.77 |
| Femur midpoint yield load (N) | 10.5 ± 0.26 | 9.95 ± 0.28 | 1.50 ± 0.02 | 10.36 ± 0.36 | 0.22 | 0.11 | 0.91 |
| Femur midpoint peak load (N) | 21.84 ± 0.60 | 20.45 ± 0.50 | 10.83 ± 0.35 | 21.41 ± 0.76 | 0.91 | 0.43 | 0.18 |
| Femur neck peak load (N) | 9.82 ± 0.38 | 9.30 ± 0.43 | 10.82 ± 0.54 | 10.08 ± 0.58 | 0.07 | 0.20 | 0.82 |
| LV2 peak load (N) | 51.6 ± 1.3 | 47.4 ± 1.3 | 51.7 ± 1.5 | 49.9 ± 2.2 | 0.43 | 0.07 | 0.44 |
| Whole femur BMC (mg) | 20.4 ± 0.49 | 19.8 ± 1.02 | 21.8 ± 0.76 | 19.5 ± 0.66 | 0.56 | 0.07 | 0.22 |
| Whole femur BMD (mg/mm2) | 6.18 ± 0.12 | 6.11 ± 0.18 | 6.46 ± 0.17 | 5.96 ± 0.12 | 0.65 | 0.07 | 0.16 |
| 1/3 prox. femur BMC (mg) | 8.00 ± 0.22 | 7.71 ± 0.37 | 8.38 ± 0.31 | 7.64 ± 0.34 | 0.61 | 0.10 | 0.48 |
| 1/3 prox. femur BMD (mg/mm2) | 6.63 ± 0.13 | 6.53 ± 0.19 | 6.88 ± 0.18 | 6.47 ± 0.13 | 0.54 | 0.12 | 0.33 |
| LV4 BMC (mg) | 6.30 ± 0.27 | 5.60 ± 0.21 | 6.39 ± 0.39 | 5.98 ± 0.25 | 0.17 | 0.55 | 0.56 |
| LV4 BMD (mg/mm2) | 5.12 ± 0.24 | 5.04 ± 0.18 | 5.29 ± 0.28 | 4.91 ± 0.10 | 0.93 | 0.27 | 0.46 |
Data are means ± SEM. Means in a row with superscripts without a common letter differ; p ≤ 0.05. Serum bone markers (n = 9–10/group); bone strength outcomes (n = 14–16/group), BMC and BMD (n = 10/group).